📄 Autonomous discovery by Cortex · 2026-05-22
"FOXO3 is a tumor suppressor frequently inactivated in aggressive cancers. Reactivating FOXO3 restores apoptosis in therapy-resistant cells."
Pathway: FOXO3 → apoptosis/cell cycle arrest → tumor suppression bypass
Clinical Angle: Restore tumor suppression in castration-resistant prostate cancer
| Metric | Value |
|---|---|
| Best Vina Score | -9.0 kcal/mol |
| Best Molecule (SMILES) | O=C(Cc1ccc2ncccc2c1)Nc1ccc(C(=O)O)c(F)c1 |
| Molecular Weight | 324.3 Da |
| QED / DCSAL | 0.707 |
| Molecules Tested | 10 |
| Docking Method | smina (real GPU, g4dn.xlarge) |
| Receptor Source | AlphaFold v4 |
Total Score: —
Prognostic: FOXO3 inactivation = poor prognosis in CRPC. CDx: FOXO3 phosphorylation status predicts PI3K inhibitor response.
| PQM Status | ISSUED |
| QCM Trust | 1.0 |
| Ledger Logged | ✅ SHA-256 hash chain |
| Evidence ID | RO-FOXO3 |
| Authority | marcus_60 (sole override) |
FOXO3 is a FIRST-IN-CLASS (0 ChEMBL) target with A+ grade binding affinity (-9.0 kcal/mol). The mechanistic hypothesis (FOXO3 → apoptosis/cell cycle arrest → tumor suppression bypass) provides a clear therapeutic rationale for Prostate / Pancreatic. Restore tumor suppression in castration-resistant prostate cancer. Recommended for wet lab validation.
MindNetQ Inc. — Governed Intelligence for Precision Medicine
Report generated by Cortex autonomous discovery pipeline. All decisions ledger-hashed.